Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29627822 | 0.87 | PTGDR2 (0.44) | ALDH1A1LMNAHIF1ATSHRHSD17B10 | |
| SCHEMBL29627816 | 0.85 | PTGDR2 (0.45) | ALDH1A1LMNAHIF1ATSHRHSD17B10 | |
| Bromide SCHEMBL3918746 | 0.85 | TSHR (0.57) | ALDH1A1TSHRHSD17B10KMT2AKDM4E | |
| Bromide SCHEMBL11599708 | 0.84 | KDM4E (0.49) | ALDH1A1LMNATSHRHSD17B10MAPT | |
| Bromide SCHEMBL17714307 | 0.83 | ABL1 (0.48) | ALDH1A1LMNAHSD17B10KMT2AKDM4E | |
| Bromide SCHEMBL17714327 | 0.83 | PLA2G2A (0.46) | ALDH1A1LMNATSHRMAPTKDM4E | |
| Bromide SCHEMBL7841361 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNAHIF1AHSD17B10KMT2A | |
| Bromide SCHEMBL4509169 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNATSHRHSD17B10KMT2A | |
| Bromide SCHEMBL31123663 | 0.81 | DPP4 (0.42) | ALDH1A1LMNATSHRHSD17B10CFTR | |
| Bromide SCHEMBL10635701 | 0.81 | ALDH1A1 (0.56) | ALDH1A1LMNATSHRMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692092-A1 | NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF | Aliad Biopharma (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024205377-A1 | NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF | 알리아드바이오파마 주식회사 | 2024-10-03 | — | — | WO | disclosed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20090105327-A1 | Dibenzocycloheptane compounds and pharmaceuticals containing these compounds | MERCKLE GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1881968-A2 | DIBENZOCYCLOHEPTANE COMPOUNDS AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | MERCKLE GMBH (DE) | 2008-01-30 | — | — | EP | disclosed |
| US-7309718-B2 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2007-12-18 | — | — | US | disclosed |
| EP-1761486-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006120010-A2 | DIBENZOCYCLOHEPTANE COMPOUNDS AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | MERCKLE GMBH (DE) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006000288-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2006-01-05 | — | — | WO | disclosed |
| US-4882351-A | CARDIOVASCULAR DISORDERS; | ROUSSEL UCLAF (FR) | 1989-11-21 | — | — | US | disclosed |
| EP-0312051-A2 | Tricyclic compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-04-19 | — | — | EP | disclosed |
| EP-0303512-A1 | Substituted dibenzocycloheptenimines | MERCK SHARP & DOHME LTD. (GB) | 1989-02-15 | — | — | EP | disclosed |
| US-4782085-A | LIPOXYGENASE INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1988-11-01 | — | — | US | disclosed |
| US-4711900-A | LIPOXYGENASE INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1987-12-08 | — | — | US | disclosed |
| EP-0244077-A1 | Sulphides derived from substituted phenyl-2-acrylic acid | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-11-04 | — | — | EP | disclosed |
| US-4474804-A | 7-Oxabicyclo substituted prostaglandin phenyl carboxylic acid derivatives useful as cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1984-10-02 | — | — | US | disclosed |
| US-4054579-A | Intermediates in the process for the preparation of 2-(5H-dibenzo[a,d]cyclohepten-5-on-2-yl)acetic, propionic and butyric acids | SYNTEX (U.S.A.) INC. (US) | 1977-10-18 | — | — | US | disclosed |
| US-4011243-A | Intermediate in the oxidative process for the preparation of 2-(5H-dibenzo[a,d]cyclohepten-5-on-2-yl)acetic, propionic and butyric acids | SYNTEX (U.S.A.) INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-3979430-A | Solvolytic process for the preparation of 2-(5H-dibenzo[a,d]cyclohepten-5-on-2-yl)acetic, propionic and butyric acids | SYNTEX (U.S.A.) INC. (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | ALDH1A1 61/4885LMNA 2120/4885HIF1A 353/4885 |
| US-20090105327-A1 | Dibenzocycloheptane compounds and pharmaceuticals containing these compounds | BDKRB1, IL1R1, IL1A | ALDH1A1 420/4885LMNA 4294/4885HIF1A 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.